Skip to main content
. Author manuscript; available in PMC: 2016 Mar 2.
Published in final edited form as: Mol Pharm. 2015 Jan 27;12(3):742–750. doi: 10.1021/mp500581r

Figure 5.

Figure 5

Normalized viability of HaCaT cells treated with siRNA/co-oligomer complexes relative to untreated cells, as determined by MTT assay over 72 h. Complexes tested at concentrations of 100 nM with respect to siRNA. Particles formulated at 4.77:1 ± charge ratio.